332 results on '"Lin, Jia-Ren"'
Search Results
2. AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
3. Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer
4. Ovarian cancer-derived IL-4 promotes immunotherapy resistance
5. Skin immune-mesenchymal interplay within tertiary lymphoid structures promotes autoimmune pathogenesis in hidradenitis suppurativa
6. A human breast atlas integrating single-cell proteomics and transcriptomics
7. Scope2Screen: Focus+Context Techniques for Pathology Tumor Assessment in Multivariate Image Data
8. MITI Minimum Information guidelines for highly multiplexed tissue images
9. High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers
10. Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma
11. Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer
12. Narrative online guides for the interpretation of digital-pathology images and tissue-atlas data
13. MITI minimum information guidelines for highly multiplexed tissue images
14. MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging
15. Temporal and spatial topography of cell proliferation in cancer
16. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma
17. Spatial Profiling of Metals through Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging
18. Fibroblast–tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways
19. The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations
20. Evolution of delayed resistance to immunotherapy in a melanoma responder
21. The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
22. Supplementary Table 4 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
23. Supplementary Figure 2 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
24. Supplementary Table 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
25. Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
26. Data from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
27. Supplementary Material 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
28. Supplementary Table 3 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
29. Supplementary Table 2 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
30. Abstract B075: Spatial genomics identifies cancer cell cytokines regulating ovarian cancer immunity
31. Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence: A Pilot Study
32. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
33. A single-cell landscape of high-grade serous ovarian cancer
34. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
35. Quality Control for Single Cell Analysis of High-plex Tissue Profiles using CyLinter
36. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
37. Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging
38. 3D multiplexed tissue imaging reconstruction and optimized region of interest (ROI) selection through deep learning model of channels embedding
39. Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
40. Figure 4 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
41. Figure 7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
42. Supplementary Fig. S2 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
43. Figure 6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
44. Figure 2 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
45. Supplementary Table S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
46. Data from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
47. Figure 5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
48. Figure 1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
49. Figure 3 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
50. Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.